A prospective cohort study of 1,483 patients transplanted for myeloid malignancies, showed significantly better two-year survival in IV-Bu recipients compared to TBI recipients: 56% vs. 48%, respectively (p=0.019).
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
IV Busulfan Better Than TBI in Pre-Transplant Conditioning
Oct 2013